Skip to content

Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01740245
Enrollment
Unknown
Registered
2012-12-04
Start date
Unknown
Completion date
Unknown
Last updated
2012-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antisepsis Regimen After Surgical Treatment of HPV Infected Lesions

Keywords

Laser therapy, Cervical lesions, Polyhexamethylene biguanide, Chlorhexidine

Brief summary

Treatments for the macroscopic or pathologic lesions caused by HPV infection can be classified as topical, surgical, destructive, or immunomodulatory. Post surgical treatments generally consist of analgesic, anti-inflammatory and topical antimicrobial agents to reduce the risk of local infections. The aim of this study is to compare the efficacy and safety of polyhexamethylene biguanide-based vaginal suppositories to a similar chlorhexidine-based treatment, in the post recovery regimen after surgical treatment of cervical lesions. Women who underwent to CO2 laser therapy for cervical lesions are randomly assigned to receive 10 days of antiseptic treatment with chlorhexidine digluconate vaginal suppositories, or polyhexamethylene biguanide vaginal suppositories (Monogin® / BiguanelleTM vaginal suppositories, Lo.Li.Pharma, Italy). A weekly follow-up check was performed for 6 weeks.

Interventions

DEVICEChlorhexidine vaginal suppositories
DEVICEPolyhexamethylene biguanide vaginal suppositories

Sponsors

AGUNCO Obstetrics and Gynecology Centre
Lead SponsorOTHER

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* positive colposcopy examination * positive Papanicolaou smear * pathological biopsy * physical ablation by CO2 laser therapy for a number of lesions included between 3 and 5

Exclusion criteria

* pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Bacterial vaginosisAfter three weeks by the day of the laser treatmentDiagnosis of eventual bacterial infection is performed according to Amsel's criteria
Change from baseline bleeding at 6 weeksAt weekly intervals by the day of laser treatmentVisual scoring was assessed depending on the grade of the defect (from 1 to 3)
Change from baseline healing process at 6 weeksAt weekly intervals by the day of laser treatmentVisual scoring for healing is assessed depending on the grade of the defect (from 1 to 3)
Change from baseline irritation status at 6 weeksAt weekly intervals by the day of laser treatmentVisual scoring for irritation is assessed depending on the grade of the defect (from 1 to 3)

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026